EcoVerify, a company that verifies and trains small businesses on sustainability and their carbon footprint, has become the first organisation in the world that can verify the carbon neutrality claims of businesses.
Laura Mora, managing director at EcoVerify, said the accreditation will help Ireland take the lead in climate action and transparency.
“In a world of shifting regulations and rising ESG (environmental, social, and governance) scrutiny, verified sustainability is no longer optional – it’s a strategic differentiator,” Ms Mora said.
“Sustainability isn’t just for the big players. SMEs verified today are tomorrow’s preferred suppliers. We are therefore delighted to achieve the certification which ensures that the confidence in the quality of services we offer to the market is fully justified.”
Set up in 2023, EcoVerify has worked with SMEs to help them comply with global sustainability standards.
The firm was granted ISO 14068-1, which outlines the various requirements for achieving carbon neutrality, by the Dutch Accreditation Council.
EcoVerify is also the first Irish-owned firm accredited under ISO 17029, which allows it to verify carbon neutrality and net-zero credentials.
It said that the new accreditation will allow the company expand its services to include tailored training and verification programmes for small businesses to strengthen their work around sustainability.
Irish medtech company OncoAssure has said it will launch its new diagnostic tool for prostate cancer into the US market.
The test is designed to help professionals assess cancer risk in their patients. It can be used to make key decisions in the treatment of cancer, post-biopsy and post-surgery.
OncoAssure, co-founded by Des O’Leary and Professor William Gallagher in 2021, made the announcement at the American Urological Association’s (AUA) annual meeting in Las Vegas.
“This launch represents a major milestone in the commercialisation of the test in the US market,” said Mr O’Leary, who is the firm’s CEO.
Des O’Leary, CEO of OncoAssure
“Access to prognostic testing remains limited for many patients in the US, making the launch of OncoAssure Prostate especially timely.
“This test addresses a critical need by providing reliable information to distinguish between aggressive and low-risk forms of prostate cancer, helping to reduce overtreatment and improve patient outcomes.”
The company, headquartered at University College Dublin’s research hub NovaUCD, will hold an investment round later this year to fund the commercialisation and continued development of its products.
Mr O’Leary said the prostate test works by identifying genes that show the progression of cancer. He said it would be easy for medical professionals to integrate it into their work.
“The OncoAssure prostate test incorporates the widely used CAPRA (Cancer of the Prostate Risk Assessment) score – a way for doctors to evaluate cancer risk – allowing seamless integration into current care pathways,” he said.
He added that it would help the company introduce more cancer detection products
“Building on this momentum, we’ve made strong progress in developing our next product, a prognostic test for skin melanoma,” he said.
source